BioSpace News Archive

As protests continue, more than half of black adults say discrimination a significant stressor

The Foundation for the National Institutes of Health has named Aviv Regev, Ph.D., winner of the 2020 Lurie Prize in Biomedical Sciences for laying the groundwork for the field of single-cell genomics and spearheading leading-edge technologies that enable a sharper perspective on human cells and applying them to revolutionize understanding of biology and disease.

Leap Therapeutics, Inc. (NASDAQ:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the pricing of an underwritten public offering of its common stock at a public offering price of $2.00 per share and of pre-funded warrants to purchase shares of its common stock at a public offering price of $1.999 per pre-funded warrant

Almirall LLC today announced that the FDA approved an important update to the Seysara® label stating that P. acnes strains displayed a low propensity for the development of resistance to sarecycline

ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Health, Inc., announced its Klarity-C preservative-free formulation may now be prescribed by Florida’s nearly 2,000 optometrists¹ as a result of the Florida Board of Optometry’s recent additions to its Formulary of Topical Ocular Pharmaceutical Agents.

Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced that two abstracts related to its clinical program for recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the upcoming Society for Pediatric Dermatology (SPD) 45 th Annual Meeting, to be held virtually during July 10-12, 2020. RDEB is a rare connective tissue disorder without an approved treatment, in which p

BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its marketing authorization application (MAA) for BRUKINSA®

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollment in its ongoing Phase 2 exploratory study of NYX-783 to evaluate the safety and efficacy of NYX-783 in patients with post-traumatic stress disorder (PTSD). The company anticipates reporting data from the study in late 2020. “The completi

Parexel and TriNetX today announced a strategic effort through which they will securely connect healthcare data to support the development of richer, actionable insights intended to accelerate the execution of clinical research

Between 2007-2017, 78 novel adult cancer agents were approved by the U.S. Food and Drug Administration,1 but none of those drugs were researched to determine effectiveness for pediatric cancers.